首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms.
【24h】

Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms.

机译:通过硫醇敏感性机制,在人类心肌病转基因兔模型中解决已建立的心脏肥大和纤维化并预防收缩功能障碍。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Cardiac hypertrophy, the clinical hallmark of hypertrophic cardiomyopathy (HCM), is a major determinant of morbidity and mortality not only in HCM but also in a number of cardiovascular diseases. There is no effective therapy for HCM and generally for cardiac hypertrophy. Myocardial oxidative stress and thiol-sensitive signaling molecules are implicated in pathogenesis of hypertrophy and fibrosis. We posit that treatment with N-acetylcysteine, a precursor of glutathione, the largest intracellular thiol pool against oxidative stress, could reverse cardiac hypertrophy and fibrosis in HCM. METHODS AND RESULTS: We treated 2-year-old beta-myosin heavy-chain Q403 transgenic rabbits with established cardiac hypertrophy and preserved systolic function with N-acetylcysteine or a placebo for 12 months (n=10 per group). Transgenic rabbits in the placebo group had cardiac hypertrophy, fibrosis, systolic dysfunction, increased oxidized to total glutathione ratio, higher levels of activated thiol-sensitive active protein kinase G, dephosphorylated nuclear factor of activated T cells (NFATc1) and phospho-p38, and reduced levels of glutathiolated cardiac alpha-actin. Treatment with N-acetylcysteine restored oxidized to total glutathione ratio, normalized levels of glutathiolated cardiac alpha-actin, reversed cardiac and myocyte hypertrophy and interstitial fibrosis, reduced the propensity for ventricular arrhythmias, prevented cardiac dysfunction, restored myocardial levels of active protein kinase G, and dephosphorylated NFATc1 and phospho-p38. CONCLUSIONS: Treatment with N-acetylcysteine, a safe prodrug against oxidation, reversed established cardiac phenotype in a transgenic rabbit model of human HCM. Because there is no effective pharmacological therapy for HCM and given that hypertrophy, fibrosis, and cardiac dysfunction are common and major predictors of clinical outcomes, the findings could have implications in various cardiovascular disorders.
机译:背景:心脏肥大是肥厚型心肌病(HCM)的临床标志,不仅是HCM的重要决定因素,也是许多心血管疾病的发病率和死亡率的主要决定因素。目前尚无有效的治疗HCM的方法,一般来说也没有治疗心肌肥大的方法。心肌氧化应激和硫醇敏感信号分子与肥大和纤维化的发病机制有关。我们认为,用N-乙酰半胱氨酸(谷胱甘肽的前体)(最大的抗氧化应激的细胞内硫醇池)进行治疗可以逆转HCM中的心脏肥大和纤维化。方法和结果:我们用心脏肥大并用N-乙酰半胱氨酸或安慰剂将收缩期功能保持2个月的2岁β-肌球蛋白重链Q403转基因兔治疗了12个月(每组n = 10)。安慰剂组的转基因兔具有心脏肥大,纤维化,收缩功能障碍,氧化谷胱甘肽比重增加,活化的硫醇敏感性活性蛋白激酶G含量升高,活化T细胞的去磷酸化核因子(NFATc1)和磷酸化p38,以及降低谷氨酰化心脏α-肌动蛋白的水平。用N-乙酰半胱氨酸治疗可恢复氧化至总谷胱甘肽比例,谷胱甘肽化的心脏α-肌动蛋白正常水平,逆转心肌和心肌细胞肥大和间质纤维化,降低室性心律不齐的倾向,预防心脏功能障碍,恢复心肌中活性蛋白激酶G的水平,以及去磷酸化的NFATc1和磷酸化p38。结论:使用N-乙酰半胱氨酸(一种安全的抗氧化前药)治疗可逆转人类HCM转基因兔模型中已建立的心脏表型。由于尚无有效的HCM药物治疗方法,并且肥大,纤维化和心脏功能障碍是常见的临床预后指标,因此该发现可能对多种心血管疾病具有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号